Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Hold” by Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been given a consensus recommendation of “Hold” by the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.60.

Several analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Citizens Jmp cut their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Monday, October 20th.

Altimmune Stock Performance

NASDAQ ALT opened at $4.24 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. The firm has a market cap of $442.40 million, a PE ratio of -3.96 and a beta of 0.04. Altimmune has a one year low of $2.90 and a one year high of $7.73. The firm’s fifty day moving average is $4.51 and its two-hundred day moving average is $4.11.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Altimmune

In other news, Director John Gill bought 12,500 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were acquired at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,250. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerome Benedict Durso purchased 12,500 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were purchased at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the purchase, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 30,527 shares of company stock valued at $125,278 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. purchased a new position in shares of Altimmune during the 3rd quarter worth approximately $38,000. BNP Paribas Financial Markets grew its holdings in Altimmune by 108.5% during the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after acquiring an additional 5,253 shares during the period. Kingswood Wealth Advisors LLC acquired a new position in Altimmune during the second quarter worth $40,000. Prudential Financial Inc. purchased a new position in Altimmune in the second quarter worth $43,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in Altimmune in the third quarter valued at $46,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.